Our preclinical studies have proven the concept of i.t. AAV9/MFSD8 gene replacement as a viable treatment strategy for the treatment of CLN7 disease when it is administered at later postnatal ages that better model intervention ages relevant to human treatment. This evidence concerns the gene MFSD8 and CLN7 disease.